In addition, because all participants were SARS-CoV-2-positive, the study design allows evaluation of CRHR1 CNVs as potential modifiers of post-COVID-19 cognitive impairment but does not permit conclusions regarding whether these CNVs are specifically related to SARS-CoV-2 infection. This evidence concerns the gene CRHR1 and Cognitive impairment.